Ep23: Chris Garabedian

Episode Summary

Executive Summary: Chris Garabedian traces his path from a middle-class Maryland upbringing and market research into senior biotech roles at Abbott, Gilead, and Celgene, emphasizing that drug success depends heavily on thoughtful development design, not just molecule quality. He contrasts company cultures, reflects on Sarepta’s turnaround, and explains Zontogeny as a “middle market” biotech builder designed to support promising founders with smaller, disciplined capital and operational expertise.

Main Topics: Early life, Armenian heritage, and education: Garabedian describes growing up in Maryland in a working/middle-class family, the son of a long-career government employee and homemaker, and later recognizing the importance of his Armenian roots and family history. Entry into biotech through market research: He explains how a marketing degree led to consumer research, then pharma market research, where he learned quantitative/qualitative methods, physician interviewing, and how prescribing decisions are shaped. Abbott and transition to biotech leadership: At Abbott he moved from brand management into new product development, learning pipeline management, go/no-go decision-making, and how business and R&D interact. Gilead, disease expertise, and product design philosophy: Garabedian recounts joining Gilead and learning hepatitis B and HIV development, forming his core belief that products are designed through experimental choices and that early design decisions shape commercial outcomes. Celgene culture and strategic breadth: He contrasts Celgene’s more expansive, risk-tolerant culture with Gilead’s efficiency, concluding that both models have strengths and influencing his later leadership approach. Sarepta turnaround and lessons from public-company leadership: Garabedian describes taking over AVI Biopharma/Sarepta as a near-dead antisense company, raising capital after early clinical data, and learning hard lessons about public-company politics, communication, and stakeholder management. Zontogeny and the biotech 'middle market': He outlines Zontogeny as a venture-like platform filling a gap between angel funding and large VC rounds, focusing on disciplined Series A financing, founder support, and improving drug-development productivity.

Key Arguments: Biotech outcomes are driven less by inherent molecule quality than by the design choices made during preclinical and clinical development. The majority of drug-development failures are not purely technical; many stem from suboptimal study design, dose selection, endpoints, formulation, or timing. Scientists and business leaders can work effectively when the business side respects scientific expertise and translates it into clinically meaningful value. Gilead’s success taught him that deep disease expertise and disciplined execution can create category leadership. Celgene showed him that a more risk-tolerant, deal-oriented culture can also generate success, informing his hybrid leadership philosophy. Sarepta’s turnaround demonstrated that good technology alone is insufficient; capital access, development decisions, and timing are crucial. Zontogeny exists to serve a neglected funding band: promising startups that need more than friends-and-family capital but less than a $50 million Series A. The industry’s real bottleneck is not ideas or money, but experienced drug-development leadership and CEO talent. A key measure of Zontogeny’s success should be improving phase-two success rates well above industry norms and building future biotech leaders.

Data Points: Year joined pharma market research: 1991 - Garabedian says he joined Migliara Kaplan Associates around 1991, marking his entry into biopharma work. Year joined Gilead: 1997 - He recalls interviewing and joining Gilead in February 1997. Year joined biotech recruiting wave: 1996-1997 - He describes being recruited by Genentech, Amgen, and Biogen before joining Gilead. Years at Abbott: About 4 years - He says he spent roughly four years at Abbott, moving from market research into new product development. Years away from work for family emergency: About 1.5 years - He took about a year and a half off after leaving Gilead due to a family emergency involving his son. Sarepta stock performance year: Top-performing biotech in 2012 - He notes the company was the top-performing biotech by stock appreciation in 2012 after early phase-two data. Initial Zontogeny capital from Perceptive: About $15 million - Luke references Garabedian raising the first roughly $15 million from Perceptive Advisors. Traditional VC A-round size mentioned: $50 million - Garabedian contrasts Zontogeny’s model with larger venture rounds of about $50 million. Middle-market Series A target: $10-15 million - He says Zontogeny targets Series A financings in the $10 million to $15 million range. Expected return example: 3-5x - He mentions a classic outcome for these projects could be a 3-to-5 times return through sale or partnership. Industry success rate goal: >50% phase-two proof-of-concept success - He says he wants Zontogeny to achieve greater than 50% success rates in phase-two clinical proof of concept. Revenue/SG&A efficiency at Gilead: 8-10x - He cites this as his internal metric for Gilead’s operating efficiency. Revenue/SG&A at next-best companies: 4-4.5x - He compares Gilead favorably to other companies he says were around 4 to 4.5x. Revenue/SG&A at Big Pharma: 2.5-3x - He characterizes large pharma efficiency as much lower than Gilead's. Portfolio size goal: 8-10 companies - He says Zontogeny sees eight to ten companies as the right portfolio mix. Foundation/friends-and-family capital: $0.5-2 million - He describes very small pre-seed financing bands that are no longer enough for many startups.

Pivotal Quotes: "the majority of the failures is based on design choices along the way" — Chris Garabedian: He explains his core philosophy that drug development outcomes are shaped by early experimental and clinical design decisions rather than fate alone. "I want to show that by choosing right and by obsessing over the design choices... that we can beat the industry averages" — Chris Garabedian: He defines Zontogeny’s success as materially improving development success rates, not just generating financial returns. "the gap we have in our industry is not a shortage of interesting technologies... Where we're really lacking is the drug development talent pool" — Chris Garabedian: He argues that the industry’s key bottleneck is leadership and execution talent, not ideas or capital.

Implications: Garabedian’s story suggests biotech value creation depends on disciplined study design, experienced operators, and the right funding model. For founders and investors, Zontogeny may offer a template for smaller, more efficient company building.